- Home
- CROX vs FOLD Comparison
CROX vs FOLD Comparison
Compare CROX & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CROX | FOLD |
|---|---|---|
| Founded | 1999 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.5B |
| IPO Year | 2005 | 2006 |
Fundamental Metrics
Financial Performance| Metric | CROX | FOLD |
|---|---|---|
| Price | $118.42 | $14.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 9 |
| Target Price | ★ $99.90 | $27.25 |
| AVG Volume (30 Days) | 1.1M | ★ 2.5M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $4,040,647,000.00 | N/A |
| Revenue This Year | $2.01 | $20.50 |
| Revenue Next Year | $2.60 | $18.59 |
| P/E Ratio | $42.96 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $73.21 | $5.66 |
| 52 Week High | $117.15 | $14.50 |
Technical Indicators
Market Signals| Indicator | CROX | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 73.60 | 74.18 |
| Support Level | $75.19 | $14.21 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 3.98 | 0.02 |
| MACD | 1.59 | -0.00 |
| Stochastic Oscillator | 93.03 | 100.00 |
Price Performance
Historical ComparisonAbout CROX Crocs Inc.
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable operating segments of the company are the Crocs Brand and the HEYDUDE Brand. The company derives maximum revenue from the Crocs brand segment.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.